Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Xiaohua Wu
- Target Recruit Count
- 30
- Registration Number
- NCT06209294
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Screening Using IMD in Bladder Cancer
- Conditions
- Interventions
- Device: Implantable Micro-DeviceDrug: MethotrexateDrug: CarboplatinDrug: AvelumabDrug: PaclitaxelDrug: VinblastineDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: CisplatinDrug: NivolumabDrug: PembrolizumabDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: ErdafitinibDrug: Paclitaxel/Docetaxel/IfosfamideDrug: GemcitabineDrug: Gemcitabine/Carboplatin/NivolumabDrug: EnfortumabDrug: Sacituzumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 46
- Registration Number
- NCT06170697
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT06162221
- Locations
- 🇺🇸
Cancer Specialists of North Florida, St Augustine, Florida, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇩🇪Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg, Germany
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 270
- Registration Number
- NCT06151574
- Locations
- 🇵🇹
Hospital CUF Porto, Porto, Portugal
🇺🇸Scripps Cancer Center Torrey Pines, La Jolla, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06140407
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 55
- Registration Number
- NCT06132113
- Locations
- 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇺🇸University of Miami, Miami, Florida, United States
🇧🇪Edegem - UNIV UZ Antwerpen, Edegem, Belgium
BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Bio-Thera Solutions
- Target Recruit Count
- 526
- Registration Number
- NCT06123884
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.